Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
Rhea-AI Summary
Zymeworks (Nasdaq: ZYME) will report fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Management will host a conference call and webcast the same day at 8:30 am Eastern Time to discuss results and provide a corporate update.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves today, with names like PGEN up 6.51% and DNTH down 1.99%, suggesting stock-specific trading rather than a coordinated biotech move around this scheduling announcement.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Conference participation | Positive | +1.5% | Announced multiple investor conference appearances in Feb–Mar 2026. |
| Jan 12 | Leadership changes | Neutral | -0.0% | Board and executive role changes to support updated corporate strategy. |
| Jan 11 | Strategy & outlook | Positive | -0.0% | Outlined 2026 strategy, Phase 3 success, milestones up to <b>$440.0M</b> and cash of <b>$270.6M</b>. |
| Jan 06 | Phase 3 results | Positive | -5.1% | Reported strong HERIZON-GEA-01 survival and PFS benefits for Ziihera combinations. |
| Dec 02 | Conference schedule | Positive | +4.5% | Announced ASCO GI and J.P. Morgan conference participation and presentation timings. |
Recent news shows positive clinical and strategic updates sometimes met with weak or negative price reactions, while conference participation headlines have drawn more supportive responses.
Over the past few months, Zymeworks has highlighted major clinical and strategic milestones, including strong Phase 3 HERIZON-GEA-01 data and eligibility for up to $440.0M in GEA regulatory milestones, plus cash and marketable securities of about $270.6M as of Dec 31, 2025. Investor events and conference participation on Dec 2, 2025 and Jan 27, 2026 saw positive price reactions. By contrast, detailed strategic and clinical updates in early January sometimes coincided with flat to negative moves, underscoring uneven sentiment heading into the upcoming earnings call.
Market Pulse Summary
This announcement set expectations for Zymeworks’ fourth quarter and full year 2025 results, scheduled for pre-market release on March 2, 2026, followed by an 8:30 am ET conference call. In recent months, the company has reported positive Phase 3 data and outlined eligibility for up to $440.0M in regulatory milestones, with cash of about $270.6M as of Dec 31, 2025. Investors may focus on how the upcoming results and guidance contextualize these prior milestones and the broader 2026 strategic outlook.
Key Terms
biotherapeutics medical
AI-generated analysis. Not financial advice.
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 2, 2026 at 8:30 am Eastern Time (ET).
About Zymeworks Inc.
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. The Company’s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Investor inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com
FAQ
When will Zymeworks (ZYME) report Q4 and full year 2025 financial results?
What time is the Zymeworks (ZYME) conference call and webcast on March 2, 2026?
How can investors access Zymeworks (ZYME) earnings conference call on March 2, 2026?
Will Zymeworks (ZYME) discuss corporate strategy during the March 2, 2026 call?
Is Zymeworks (ZYME) releasing earnings before or after market open on March 2, 2026?
What should shareholders expect from Zymeworks (ZYME) March 2, 2026 webcast?
